Stem Cells International

Stem Cells International / 2015 / Article

Review Article | Open Access

Volume 2015 |Article ID 219514 |

Amar M. Singh, "Cell Cycle-Driven Heterogeneity: On the Road to Demystifying the Transitions between “Poised” and “Restricted” Pluripotent Cell States", Stem Cells International, vol. 2015, Article ID 219514, 9 pages, 2015.

Cell Cycle-Driven Heterogeneity: On the Road to Demystifying the Transitions between “Poised” and “Restricted” Pluripotent Cell States

Academic Editor: Bernard A. J. Roelen
Received19 Feb 2015
Revised25 Mar 2015
Accepted26 Mar 2015
Published05 Apr 2015


Cellular heterogeneity is now considered an inherent property of most stem cell types, including pluripotent stem cells, somatic stem cells, and cancer stem cells, and this heterogeneity can exist at the epigenetic, transcriptional, and posttranscriptional levels. Several studies have indicated that the stochastic activation of signaling networks may promote heterogeneity and further that this heterogeneity may be reduced by their inhibition. But why different cells in the same culture respond in a nonuniform manner to the identical exogenous signals has remained unclear. Recent studies now demonstrate that the cell cycle position directly influences lineage specification and specifically that pluripotent stem cells initiate their differentiation from the G1 phase. These studies suggest that cells in G1 are uniquely “poised” to undergo cell specification. G1 cells are therefore more prone to respond to differentiation cues, which may explain the heterogeneity of developmental factors, such as Gata6, and pluripotency factors, such as Nanog, in stem cell cultures. Overall, this raises the possibility that G1 serves as a “Differentiation Induction Point.” In this review, we will reexamine the literature describing heterogeneity of pluripotent stem cells, while highlighting the role of the cell cycle as a major determinant.

1. Introduction

Pluripotent stem cells (PSCs) have two defining characteristics, the ability to undergo indefinite self-renewal and the capacity to differentiate into the cells belonging to all 3 germ layers of the embryo: the mesoderm, endoderm, and ectoderm cell lineages [1]. Understanding the mechanisms that govern the processes of self-renewal and lineage specification continues to be a major focus for stem cell biologists, as these cells have tremendous potential for utility in cell-based therapies, disease modeling, and exploring the basic principles regulating early embryonic development and cell-fate commitment.

The classical paradigm describing the relationship between self-renewal and differentiation establishes that (1) a core set of pluripotency transcription factors are expressed to maintain self-renewal and suppress differentiation and (2) lineage-specific transcription factors become expressed to initiate differentiation following signaling cues [1]. Subsequently, upon differentiation, pluripotency factors are rapidly downregulated. This simple and elegant model, however, does not adequately explain the mechanisms describing the exit from pluripotency, and moreover, a number of recent studies challenge this classical view. First, several studies show that pluripotency factors may have a direct role in promoting differentiation to different cell lineages [24]. These studies raise the possibility that the so-called “pluripotency factors” have a role not only in maintaining self-renewal, but also in driving lineage specification to exit the pluripotent state. Secondly, recent studies in the field of reprogramming have demonstrated that you can reestablish the pluripotent state by the expression of lineage specifiers [5, 6]. In this model the expression of developmental factors suppresses alternate cell lineages promoting a pluripotent state. Thirdly, the recent identification of F-class pluripotent cells [7, 8], which have so far only been established during reprogramming, demonstrates that high and stably maintained expression of Oct4, Sox2, KLF4, and Myc promotes a self-renewing pluripotent cell. This F-class PSC is distinct from all other pluripotent cell types and expresses numerous lineage markers. Together these discoveries suggest that the traditional view and relationship between self-renewal and differentiation are not so clear-cut.

The classical notion of self-renewal and differentiation has also been challenged by the discovery of cellular heterogeneity within clonal stem cell cultures [911]. For example, several pluripotency factors have been shown to transition between “low” and “high” states in their expression levels during culture (see further details below). This heterogeneity of pluripotency factor expression during self-renewal indicates that the static expression of pluripotency factors is not a central requirement to maintaining pluripotency and inhibiting differentiation. Furthermore, the expression of developmental transcription factors has also been found to be transiently present during stem cell cultures. This so-called “metastability” of transcription factors during stem cell self-renewal is thought to be due to stochastic effects of signaling networks. While the importance of signaling networks is clear, recent studies by us, and others, now indicate that cell cycle positional effects also have a central role in promoting heterogeneity within stem cell cultures [12, 13].

2. Pluripotent Stem Cells and Their Atypical Cell Cycle

Numerous different types of pluripotent stem cells have been identified, either by direct isolation from embryos or by the reprogramming of somatic cells back to a pluripotent state [10]. The pluripotency status of these cells can range from the naïve/ground state pluripotent cells, such as mouse embryonic stem cells (mESCs) grown in 2i/Lif media [14], to the primed pluripotent stem cells derived from the epiblast, such as epiblast stem cells (EpiSCs) or human embryonic stem cells (hESCs, see Figure 1) [1517]. By reprogramming, the F-class pluripotent state has also been identified [7, 8]. This state appears to be distinct from partially reprogrammed cells, expresses some but not all pluripotency markers, and generally expresses more lineage factors. Although it is unclear if this cell type exists in vivo, these cells are projected to be further down on the spectrum of pluripotency than the primed/epiblast-like cells. These data indicate that PSCs exist in a continuum of different cell states [18].

Regardless of their pluripotency status, PSCs typically have a unique cell cycle. We will only briefly consider this topic as numerous reviews examine this in considerable detail [1921]. The cell cycle of mammalian PSCs is characterized by a short G1 phase and a large percentage of S phase cells [22]. Upon differentiation, the cell cycle undergoes a restructuring such that G1 lengthens and the number of cells in S phase is reduced [23, 24]. The molecular mechanism underlying this principle has been extensively examined with mESCs in traditional Lif/serum-containing media and to some extent in hESCs. Unlike somatic cells, which rely on mitogenic signaling from Fgf/Erk signaling, mESCs typically undergo differentiation from elevated Erk activity [25]. Instead mESCs rely on signals from PI3-kinase/Akt signaling, generated from factors such as insulin [14], to promote the cell cycle. Similarly hESCs also depend on PI3-kinase/Akt activity, which maintains Fgf/Erk signaling below a threshold required for differentiation [26, 27]. This notion is supported by studies using PTEN knockout mESCs, which proliferate rapidly [28]. Mouse PSCs do not appear to have an intact restriction (R) point as (1) E2F target genes appear to be stable throughout the cells cycle, (2) retinoblastoma protein (Rb) is stably hyperphosphorylated and inactive, and (3) Cdk2 expression and activity are in an elevated state [19]. On the other hand, hESCs do appear to have some Rb/E2F activity and may have a restriction point, but this is still not well understood [2931]. Altogether these findings establish a mechanism for why pluripotent stem cells spend 50–80% of their time in S phase and only 10–20% of their time in G1. But how does this unusual cell cycle relate to cell specification?

Christine Mummery first described an intriguing relationship between the cell cycle and differentiation using embryonal carcinoma cells in 1987 [32]. Her work suggested that cells in G1 were more prone to initiate differentiation from signaling cues, such as retinoic acid, while cells in S phase were refractory to retinoic acid signaling. This discovery, that cells initiate differentiation from G1, has now been validated by several independent studies in human embryonic stem cells [12, 13, 33, 34]. Several recent studies utilize the Fucci (fluorescent ubiquitinated cell cycle indicator [35]) reporter system in ESCs to examine the relationship between the cell cycle, pluripotency, and differentiation [12, 13, 3638] (Figure 2). Importantly, the Fucci system allows you to monitor and isolate cell cycle fractions from live cells, without the need for cell synchronization by chemical inhibitors such as nocodazole and aphidicolin. This provides a significant advantage over chemical blocks, as the cells remain unperturbed, thus minimizing artificial and nonspecific side effects. These studies indicate that G1 provides a “window of opportunity” where cells may commit to differentiation or continue to self-renew depending on signaling cues [12, 13, 39]. These studies provide a potential explanation as to why PSCs spend the majority of their time in S phase (i.e., to prevent unwarranted differentiation) and further suggest that G1 cells are in a “poised” state, such that they may commit to lineage specification. Together these studies establish the possibility that the cell cycle has a role in controlling cell state transitions and the “metastable” state of pluripotency.

Most, if not all, pluripotent stem cell subtypes appear to exist in a “metastable” state, where they undergo transitions between a “lineage-poised” state and a “lineage-restricted” state, which is dependent upon the cell cycle position (Figure 1). In this hypothetical model, I am making a clear distinction between the terminologies for “primed” versus “poised” pluripotent cells. A “primed” pluripotent cell refers strictly to those cells emanating from, or most reminiscent of, cells from the epiblast stage of the postimplantation blastocyst. Primed cells represent a window of time during embryonic development (or in vitro differentiation/reprogramming) on the spectrum of pluripotency. On the other end of the pluripotency spectrum are “naïve” cells, which are reminiscent of cells belonging to the inner cells mass of a peri-implantation blastocyst. “Poised” pluripotent cells refer to a cell that is ready to commit to differentiation and in the G1 phase. Poised cells express higher levels of lineage markers [12] and potentially reduced levels of pluripotency markers (discussed below). Poised cells are more responsive to differentiation-inducing signaling cues [12, 13, 3234]. Furthermore, the epigenetic status and potentially chromatin structure within poised cells may be distinct or more amenable to rearrangement [12], permitting cell-fate specification. The converse of the poised state would be the “restricted” state, where cells exhibit reduced lineage marker expression and increased pluripotency marker expression and are primarily in S-G2 phases of the cell cycle [12]. These cells should be less susceptible to differentiation signaling cues and thus maintained in a protected state. Therefore, the terms “poised” and “restricted” refer to different positions on the spectrum of heterogeneity, which directly correlates with the cell cycle position. In this hypothetical model, both “naïve” and “primed” cells transition between “poised” and “restricted” states, as they progress through cell cycle stages (Figure 1). We will examine the evidence that support this model in the subsequent sections.

3. Heterogeneity of Pluripotency Factors

Numerous reviews have summarized the findings with regard to heterogeneity in pluripotent stem cell populations [9, 11, 4044], so we will pay special attention to those studies that have uncovered a relationship with the cell cycle. Several pluripotency factors have been found to be heterogeneously expressed in PSCs, including Nanog [4547], Rex1 [48], Oct4 [49], Stella [44], Esrrb [50, 51], KLF4 [52], and ZSCAN4 [53]. Three studies initially identified Nanog protein as being heterogeneously expressed during the traditional culture (Lif/serum) of mESCs [4547]. Importantly, two of these studies showed by knock-in reporter systems that Nanog could transition between Nanog-low and Nanog-high states [46, 47]. These findings were confirmed by others and used in computational modeling to predict the mechanics of these gene fluctuations [54, 55].

Several mechanisms have been attributed to the transition of Nanog between low and high states. One of the more intriguing models suggests that Nanog transcription is regulated at the allelic level [56]. Using fluorescent reporters under control of the Nanog promoter, Miyanari and Torres-Padilla found that Nanog is monoallelically expressed in mESCs in Lif/serum media but then switches to a biallelic expression as cells transition back towards a naïve stem cell state in 2i/Lif media. While initial single-cell RNA-sequencing studies failed to confirm these findings [57], other single-cell assays have also found fluctuations in pluripotency markers, including Nanog [18, 51]. Knock-in fluorescent proteins fused to Nanog also are not supportive of monoallelic expression variations [58]. However, half-lives of monoallelic transcript and protein, along with protein and RNA stability, may be considerably different [41, 59], although Nanog RNA and protein levels appear to correlate well [60]. Allelic expression patterns may not be the sole determinant of Nanog heterogeneity, however, as heterogeneity of Nanog may persist in 2i/Lif media [61] where biallelic expression occurs. Other possible mechanisms, such as the cell cycle and signaling environment, may then have a role in controlling Nanog heterogeneity.

What is the relationship between Nanog and the cell cycle? Our initial study, which identified Nanog heterogeneity and suggested that Nanog-low and Nanog-high mouse ESCs could interconvert in Lif/serum media [47], evaluated the gene expression patterns between Nanog-low and Nanog-high cells using microarrays. Interestingly, we found that numerous cell cycle genes were elevated in the Nanog-high cells. These included Cyclin B1, Aurora Kinase B, E2F1, and Wee1, which are genes that are well known to be elevated in S and G2 phases of the cell cycle. Nanog-low cells, on the other hand, expressed CDK inhibitors 1C and 2B [47], which are commonly found in G1. When Nanog-low cells were replated at limiting dilution concentrations, nearly all cells were able to reestablish colonies with cells expressing the Nanog reporter [47]. While this reduces the likelihood that contaminating differentiated cells exist within the Nanog-low subpopulations, this caveat however cannot be completely excluded. Overall, these observations raise the hypothesis that Nanog expression may fluctuate during the cell cycle in mouse ESCs grown in Lif/serum. We found that Nanog-low cells ranged from 5 to 10% of the total culture, which would be consistent with the percentage of cells in G1 [47]. In agreement with these findings, work by Macarthur and colleagues [55] demonstrates that the depletion of Nanog, using an inducible system, leads to an accumulation of cell cycle checkpoint genes, such as CDK inhibitors 1A, 1B, and 2A, suggesting an arrest in G1 [55]. Importantly, the reintroduction of Nanog led to a loss of the cell cycle checkpoint genes. Recently, Nanog expression, but not Oct4, has been shown to be dynamic during the cell cycle in mESCs [62]. Although the data relied on chemical blocks, which may have unwarranted effects, further confirmation is necessary.

In hESCs, Nanog has been shown to directly control the expression of cell cycle genes, CDK6 and CDC25A, and therefore regulate the G1 to S phase transition [63]. In addition, the pluripotency network consisting of Oct4, NANOG, and SOX2 was also found to regulate the miR-302 cluster [64]. Loss of miR-302 led to an increase in G1 cells, which was mediated by an accumulation of Cyclin D1. Together these findings suggest that the pluripotency network controls the cell cycle transitions and the length of G1. By using the Fucci system in hESCs, we have not observed any changes to NANOG transcript or protein levels during the cell cycle [12]. However, given the proposed differences in Nanog allelic expression between mESCs in traditional Lif/serum media and epiblast-like cells [56], and the differences in signaling requirements for these pluripotent cell types, this raises the possibility that Nanog may be cell cycle regulated in peri-implantation blastocyst embryos and stabilized at the postimplantation epiblast stage. In this scenario, the cell cycle position may also influence the allelic expression patterns. Another possibility is that stochastic promoter activity associated with Nanog in mESCs [60] becomes stabilized as cells move further down the continuum of pluripotency, which may be important for Nanog’s role in lineage specification [2, 3]. In either case, more studies examining the relationship between Nanog and the cell cycle are warranted.

Other pluripotency factors, which are expressed heterogeneously, have also been suggested to control the cell cycle. For example, the deletion of Rex1 in mESCs was found to result in increased expression levels for Cyclin D2 and Cdk inhibitor 2B and decreased Cyclin E2 [65], consistent with increased number of G1 cells and a decreased number in S-G2. Interestingly, Nanog-low cells exhibit reduced expression levels for Rex1 [47], and Rex1-low cells were found to have reduced expression levels for Nanog [48]. Altogether these studies may suggest the occurrence of a G1-subpopulation that is low in pluripotency marker expression. Finally, another potential pluripotent factor that may regulate the cell cycle is KLF4. In particular KLF4 is thought to regulate the cell cycle checkpoint controls including G2/M in nonpluripotent cell types [66]. However, no studies have yet examined the role of KLF4 in controlling the cell cycle in pluripotent populations.

Other studies have also identified a relationship between the pluripotency marker SSEA3 and the cell cycle in hESCs [67]. Bhatia and colleagues used SSEA3 to isolate SSEA3− and SSEA3+ subpopulations and subsequently performed cell cycle analyses. Importantly, SSEA3− populations were heavily enriched in G1 cells, while SSEA3+ populations were enriched in S-G2/M cells, and these populations could interconvert between each other. Furthermore, both Nanog and Oct4 protein (but not transcript) were elevated in the SSEA3+ population, over the SSEA3− population. Overall, these studies support the hypothesis that pluripotency markers are cell cycle regulated and become diminished in G1 to establish a “poised” pluripotent state. This provides a plausible explanation for their apparent heterogeneity of pluripotency factors under certain signaling conditions.

4. Heterogeneity of Developmental Factors

Background expression levels of developmental factors can be readily identified during the culture of PSCs. This background level, however, is not usually ubiquitous in all cells and instead heterogeneously expressed in only a small subset of cells. The heterogeneity of developmental factors has been observed for Gata6 [12, 47], Sox17 [12, 68], FOXA2 [12], HEX [69], Hes1 [70], and BRACHYURY [26]. Furthermore, single-cell expression analysis in hESCs has identified lineage-primed subpopulations, in which developmental genes are expressed [71].

While signaling network dynamics clearly have a role in promoting heterogeneity among developmental factors (discussed below), we have found that the cell cycle position has a direct role [12]. By using the Fucci system in hESCs and performing RNA-sequencing in cell cycle fractions, we observed that numerous developmental genes for all 3 germ layers were cell cycle regulated, and this cell cycle regulation persisted during differentiation (Figure 2). Moreover, most of these developmental genes peaked in the G1 phase of the cell cycle. This is consistent with cells initiating their differentiation from the G1 phase [12, 13, 3234] and establishes G1 as the poised pluripotent state.

One important question that remains is as follows: do these developmental genes have a role in regulating the cell cycle or reorganizing the cell cycle structure as cells differentiate? While this is difficult to address, since deletion of these genes can sometimes block differentiation, this will be pertinent to further understand the relationship between lineage specification and the cell cycle. Further global studies that identify the target genes for early developmental regulators during PSC differentiation should shed light on this question.

5. Signaling Networks and Their Effect on Heterogeneity

Stochastic activity of signaling networks is considered to be the major contributing determinant to cellular heterogeneity in stem cell cultures. Heterogeneity of pluripotency and developmental factors in mESCs were initially observed in serum-based media, where signaling effectors are indeterminable. However, when mESCs were grown in defined media conditions in the presence of Mek/Erk and Gsk3 inhibitors (2i/Lif), a considerable reduction in heterogeneity has been observed [14, 72]. In particular, the background expression of developmental genes for all germ layers is reduced. Furthermore, there is a significant loss of H3K27me3 and fewer bivalent domains altogether. Based on these findings, mESCs in 2i/Lif media are considered to be in a naïve or ground state (Figure 1). Given the importance of Erk activity in development [25] and Wnt signaling in mESC self-renewal [7376], the reduction of developmental gene expression in 2i/Lif media is not too surprising. However, all heterogeneity is not lost in 2i/Lif media, as Nanog still fluctuates [61]; some developmental genes such as GSC are still expressed [72], and developmental reporters for Hex are still heterogeneously present [11, 69]. Together these data would suggest that other factors besides cell signaling, such as a cell’s position within the cell cycle, are also of critical importance.

Unlike Erk signaling, the role of Wnt signaling in ESC self-renewal and differentiation is more complex, with some findings suggesting it promotes self-renewal and other findings suggesting it promotes differentiation. This may be directly due to concentration dependent effects of Gsk3 inhibitors used to mimic Wnt signaling. At high concentrations of Gsk3, β-catenin-dependent signaling is heavily activated which promotes differentiation [26, 77, 78], while at lower doses Myc or β-catenin/Tcf3 complexes are stabilized, which promotes self-renewal. Exogenous expression of Wnt3a promotes the expression of pluripotency and endoderm genes, resulting in increased heterogeneity mediated through Tbx3 [79]. Furthermore, β-catenin has also been found to fluctuate in mESCs and contribute to Nanog heterogeneity [80]. These data clearly indicate an important role for Wnt signaling in promoting heterogeneity of stem cells.

In hESCs, endogenous WNT signaling is well documented to promote heterogeneity within stem cell cultures [26, 81, 82], and inhibition of WNT signaling with antagonists, such as DKK1 and XAV939, significantly reduces the heterogeneous expression of developmental genes such as GATA6, SOX17, and BRACHYURY. Interestingly, while we have found that GATA6 and SOX17 are cell cycle regulated, BRACHYURY is not, which may indicate that there are multiple layers of heterogeneity [12]. One explanation for this may be due to the requirement for specific β-catenin cofactors necessary for transcriptional activation. For example, in some cases SMAD2,3 may be a corequirement for β-CATENIN, such as for endoderm genes like MIXL1 [26], while other genes may require a different set of cofactors. Recent work has shown that SMAD2,3 shuttles in and out of the nucleus in a cell cycle-dependent manner, and this is dependent upon CDK4/6 activity [13]. This provides one explanation for the cell cycle regulation of GATA6 and SOX17 transcripts, and cell cycle-independence of BRACHYURY transcript, as GATA6 and SOX17, but not BRACHYURY, may be dependent upon ACTIVIN/SMAD2,3 signaling.

A recent study by Hough et al. utilized single-cell sequencing from subpopulations of cells separated based on cell surface molecules, GCTM2, CD9, and EPCAM, to examine heterogeneity in hESCs grown under different self-renewal media conditions [71]. In addition to observing heterogeneity with pluripotent and developmental factors, they also observed heterogeneity among signaling molecules, and especially those belonging to the TGF-beta superfamily. Importantly, they confirmed this heterogeneity at the protein level by immunostaining. This provides evidence that the activity of signaling networks may vary on a cell-to-cell basis. Since the cell cycle has a role in controlling heterogeneity, one hypothesis here is that the cell cycle may control signaling pathway activities, but further studies are needed here. It should also not be overlooked that within the TGF-beta superfamily, competing Nodal and BMP signals can regulate the heterogeneity of pluripotency factors, such as Nanog [83].

We have found that the position of a cell, within the cell cycle, directly effects heterogeneity caused by WNT signaling and ERK signaling [12]. The inhibition of WNT activity, by DKK1, or MEK/ERK activity, by U0126, significantly reduces heterogeneity of GATA6, SOX17, and FOXA2 found in G1 cells. Again, these data raise the hypothesis that a cell becomes poised in G1, which makes them more permissive to respond to differentiation-inducing signals by WNT or ERK. The end result is the heterogeneous expression of developmental factors. Overall, it is clear that signaling networks are directly required for promoting heterogeneity within stem cell subpopulations, where in many cases the subpopulation is determined by the cell cycle position.

6. Conclusion and Future Perspectives

It is now becoming increasingly clear that heterogeneity is a natural part of pluripotency [12, 84]. In many cases, this heterogeneity is a direct result of a cell transitioning through different phases of the cell cycle. After a cell completes mitosis and enters into G1, it becomes “poised.” This cell-poising likely reflects different epigenetic and chromatin configurations, which allows the cell to be permissive to either continue self-renewing or commit to lineage specification. This cell-fate choice is entirely dependent on the signaling environment. As the cell further progresses into S phase, the cell becomes less responsive to differentiation cues and is now in a “restricted” state. Why a cell must be in a “restricted” state in S and G2 is less clear, but this may have to do with temporal control and the importance of maintaining error-free gene duplication. G1 is often the focus of a cell’s decision making center as the restriction point [85] and also the replication timing and the chromatin architecture [86, 87] are established here. Therefore we may consider G1 to be the “Differentiation Induction Point” for pluripotent stem cells.

Examining the molecular determinants controlling heterogeneity of pluripotent stem cells has been considerably helped by several studies utilizing single-cell RNA-sequencing [51, 57, 71]. However, the hurdle of technical variability with this methodology should not be overlooked [88]. Also, the cell cycle position can also lead to unwanted noise and can be reduced through computational algorithms [89]. Nonetheless, the utility of single-cell approaches to understand that heterogeneity is clear. Obtaining a full appreciation of the complexities with regard to the dynamic nature of epigenetic marks, at the single-cell level, remains a necessary hurdle yet to be overcome. Indeed we have found that 5-hydroxymethylcytosine (5hmC) is dynamic during the cell cycle [12]. Recent advances with single-cell DNA methylation approaches [90, 91] and single-cell chromatin structure techniques [92] will be essential for further studies in heterogeneity, but methods to determine genome-wide distribution for histone modifications in single-cells still need to be developed.

The role of the cell cycle in controlling posttranscriptional regulation of genes has also not been elucidated. We have identified two proteins, FOXA2 and SOX17, which oscillate during the cells cycle [12]. How these proteins are turned over in a cell cycle-dependent manner remains to be determined. Proteomics-based approaches aiming at the global identification of proteins that fluctuate during the cell cycle from pluripotent stem cells would present additional insight. Furthermore, the identification of posttranslational modifications, and their targets, that occur in a cell cycle-dependent manner will be important for future studies. Altogether, “omics” approaches will be critical in the future to understand the underlying mechanisms regulating heterogeneity and cell-fate specification.

In this paper, I have outlined the current understanding of the relationship between heterogeneity, the cell cycle, and lineage determination. It is clear that both the cell cycle position and the signaling networks converge to promote heterogeneity of developmental factors. While there is some evidence that pluripotency factors may oscillate during the cell cycle, further studies are still needed here. Clearly, however, pluripotency factors have a role in regulating cell cycle progression. In summary, the cell cycle position provides a direct explanation for metastability in stem cell cultures, which is necessary to regulate cell-fate commitment.

Conflict of Interests

The author declares that there is no conflict of interests regarding the publication of this paper.


The author would like to thank Stephen Dalton, Naohiro Terada, and numerous colleagues over the years for their helpful discussions.


  1. A. G. Smith, “Embryo-derived stem cells: of mice and men,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 435–462, 2001. View at: Publisher Site | Google Scholar
  2. A. K. K. Teo, S. J. Arnold, M. W. B. Trotter et al., “Pluripotency factors regulate definitive endoderm specification through eomesodermin,” Genes and Development, vol. 25, no. 3, pp. 238–250, 2011. View at: Publisher Site | Google Scholar
  3. M. Thomson, S. J. Liu, L.-N. Zou, Z. Smith, A. Meissner, and S. Ramanathan, “Pluripotency factors in embryonic stem cells regulate differentiation into germ layers,” Cell, vol. 145, no. 6, pp. 875–889, 2011. View at: Publisher Site | Google Scholar
  4. G. C. Le Bin, S. Muñoz-Descalzo, A. Kurowski et al., “Oct4 is required for lineage priming in the developing inner cell mass of the mouse blastocyst,” Development, vol. 141, no. 5, pp. 1001–1010, 2014. View at: Publisher Site | Google Scholar
  5. J. Shu, C. Wu, Y. Wu et al., “XInduction of pluripotency in mouse somatic cells with lineage specifiers,” Cell, vol. 153, no. 5, pp. 963–975, 2013. View at: Publisher Site | Google Scholar
  6. N. Montserrat, E. Nivet, I. Sancho-Martinez et al., “Reprogramming of human fibroblasts to pluripotency with lineage specifiers,” Cell Stem Cell, vol. 13, no. 3, pp. 341–350, 2013. View at: Publisher Site | Google Scholar
  7. P. D. Tonge, A. J. Corso, C. Monetti et al., “Divergent reprogramming routes lead to alternative stem-cell states,” Nature, vol. 516, no. 7530, pp. 192–197, 2014. View at: Publisher Site | Google Scholar
  8. S. M. I. Hussein, M. C. Puri, P. D. Tonge et al., “Genome-wide characterization of the routes to pluripotency,” Nature, vol. 516, no. 7530, pp. 198–206, 2014. View at: Publisher Site | Google Scholar
  9. T. Graf and M. Stadtfeld, “Heterogeneity of embryonic and adult stem cells,” Cell Stem Cell, vol. 3, no. 5, pp. 480–483, 2008. View at: Publisher Site | Google Scholar
  10. P. Cahan and G. Q. Daley, “Origins and implications of pluripotent stem cell variability and heterogeneity,” Nature Reviews Molecular Cell Biology, vol. 14, no. 6, pp. 357–368, 2013. View at: Publisher Site | Google Scholar
  11. A. Martinez Arias and J. M. Brickman, “Gene expression heterogeneities in embryonic stem cell populations: origin and function,” Current Opinion in Cell Biology, vol. 23, no. 6, pp. 650–656, 2011. View at: Publisher Site | Google Scholar
  12. A. M. Singh, J. Chappell, R. Trost et al., “Cell-cycle control of developmentally regulated transcription factors accounts for heterogeneity in human pluripotent cells,” Stem Cell Reports, vol. 1, no. 6, pp. 532–544, 2013. View at: Publisher Site | Google Scholar
  13. S. Pauklin and L. Vallier, “The cell-cycle state of stem cells determines cell fate propensity,” Cell, vol. 155, no. 1, pp. 135–147, 2013. View at: Publisher Site | Google Scholar
  14. Q.-L. Ying, J. Wray, J. Nichols et al., “The ground state of embryonic stem cell self-renewal,” Nature, vol. 453, no. 7194, pp. 519–523, 2008. View at: Publisher Site | Google Scholar
  15. P. J. Tesar, J. G. Chenoweth, F. A. Brook et al., “New cell lines from mouse epiblast share defining features with human embryonic stem cells,” Nature, vol. 448, no. 7150, pp. 196–199, 2007. View at: Publisher Site | Google Scholar
  16. I. G. M. Brons, L. E. Smithers, M. W. B. Trotter et al., “Derivation of pluripotent epiblast stem cells from mammalian embryos,” Nature, vol. 448, no. 7150, pp. 191–195, 2007. View at: Publisher Site | Google Scholar
  17. J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., “Embryonic stem cell lines derived from human blastocysts,” Science, vol. 282, no. 5391, pp. 1145–1147, 1998. View at: Publisher Site | Google Scholar
  18. S. R. Hough, A. L. Laslett, S. B. Grimmond, G. Kolle, and M. F. Pera, “A continuum of cell states spans pluripotency and lineage commitment in human embryonic stem cells,” PLoS ONE, vol. 4, no. 11, Article ID e7708, 2009. View at: Publisher Site | Google Scholar
  19. A. M. Singh and S. Dalton, “The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming,” Cell Stem Cell, vol. 5, no. 2, pp. 141–149, 2009. View at: Publisher Site | Google Scholar
  20. K. Kapinas, R. Grandy, P. Ghule et al., “The abbreviated pluripotent cell cycle,” Journal of Cellular Physiology, vol. 228, no. 1, pp. 9–20, 2013. View at: Publisher Site | Google Scholar
  21. I. Neganova and M. Lako, “G1 to S phase cell cycle transition in somatic and embryonic stem cells,” Journal of Anatomy, vol. 213, no. 1, pp. 30–44, 2008. View at: Publisher Site | Google Scholar
  22. J. White and S. Dalton, “Cell cycle control of embryonic stem cells,” Stem Cell Reviews, vol. 1, no. 2, pp. 131–138, 2005. View at: Publisher Site | Google Scholar
  23. E. Stead, J. White, R. Faast et al., “Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities,” Oncogene, vol. 21, no. 54, pp. 8320–8333, 2002. View at: Publisher Site | Google Scholar
  24. P. Savatier, H. Lapillonne, L. A. van Grunsven, B. B. Rudkin, and J. Samarut, “Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells,” Oncogene, vol. 12, no. 2, pp. 309–322, 1996. View at: Google Scholar
  25. T. Kunath, M. K. Saba-El-Leil, M. Almousailleakh, J. Wray, S. Meloche, and A. Smith, “FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment,” Development, vol. 134, no. 16, pp. 2895–2902, 2007. View at: Publisher Site | Google Scholar
  26. A. M. Singh, D. Reynolds, T. Cliff et al., “Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation,” Cell Stem Cell, vol. 10, no. 3, pp. 312–326, 2012. View at: Publisher Site | Google Scholar
  27. S. Dalton, “Signaling networks in human pluripotent stem cells,” Current Opinion in Cell Biology, vol. 25, no. 2, pp. 241–246, 2013. View at: Publisher Site | Google Scholar
  28. H. Sun, R. Lesche, D. M. Li et al., “PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6199–6204, 1999. View at: Publisher Site | Google Scholar
  29. K. A. Becker, P. N. Ghule, J. A. Therrien et al., “Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase,” Journal of Cellular Physiology, vol. 209, no. 3, pp. 883–893, 2006. View at: Publisher Site | Google Scholar
  30. P. N. Ghule, K. A. Becker, J. W. Harper et al., “Cell cycle dependent phosphorylation and subnuclear organization of the histone gene regulator p220NPAT in human embryonic stem cells,” Journal of Cellular Physiology, vol. 213, no. 1, pp. 9–17, 2007. View at: Publisher Site | Google Scholar
  31. I. Neganova, X. Zhang, S. Atkinson, and M. Lako, “Expression and functional analysis of G1 to S regulatory components reveals an important role for CDK2 in cell cycle regulation in human embryonic stem cells,” Oncogene, vol. 28, no. 1, pp. 20–30, 2009. View at: Publisher Site | Google Scholar
  32. C. L. Mummery, M. A. van Rooijen, S. E. van den Brink, and S. W. de Laat, “Cell cycle analysis during retinoic acid induced differentiation of a human embryonal carcinoma-derived cell line,” Cell Differentiation, vol. 20, no. 2, pp. 153–160, 1987. View at: Publisher Site | Google Scholar
  33. Y. Sela, N. Molotski, S. Golan, J. Itskovitz-Eldor, and Y. Soen, “Human embryonic stem cells exhibit increased propensity to differentiate during the G1 phase prior to phosphorylation of retinoblastoma protein,” Stem Cells, vol. 30, no. 6, pp. 1097–1108, 2012. View at: Publisher Site | Google Scholar
  34. S. Chetty, F. W. Pagliuca, C. Honore, A. Kweudjeu, A. Rezania, and D. A. Melton, “A simple tool to improve pluripotent stem cell differentiation,” Nature Methods, vol. 10, no. 6, pp. 553–556, 2013. View at: Publisher Site | Google Scholar
  35. A. Sakaue-Sawano, H. Kurokawa, T. Morimura et al., “Visualizing spatiotemporal dynamics of multicellular cell-cycle progression,” Cell, vol. 132, no. 3, pp. 487–498, 2008. View at: Publisher Site | Google Scholar
  36. A. Calder, I. Roth-Albin, S. Bhatia et al., “Lengthened G1 phase indicates differentiation status in human embryonic stem cells,” Stem Cells and Development, vol. 22, no. 2, pp. 279–295, 2013. View at: Publisher Site | Google Scholar
  37. D. Coronado, M. Godet, P.-Y. Bourillot et al., “A short G1 phase is an intrinsic determinant of naïve embryonic stem cell pluripotency,” Stem Cell Research, vol. 10, no. 1, pp. 118–131, 2013. View at: Publisher Site | Google Scholar
  38. M. Roccio, D. Schmitter, M. Knobloch, Y. Okawa, D. Sage, and M. P. Lutolf, “Predicting stem cell fate changes by differential cell cycle progression patterns,” Development, vol. 140, no. 2, pp. 459–470, 2013. View at: Publisher Site | Google Scholar
  39. S. Dalton, “G1 compartmentalization and cell fate coordination,” Cell, vol. 155, no. 1, pp. 13–14, 2013. View at: Publisher Site | Google Scholar
  40. Y. Nakai-Futatsugi and H. Niwa, “Transcription factor network in embryonic stem cells: heterogeneity under the stringency,” Biological and Pharmaceutical Bulletin, vol. 36, no. 2, pp. 166–170, 2013. View at: Publisher Site | Google Scholar
  41. M.-E. Torres-Padilla and I. Chambers, “Transcription factor heterogeneity in pluripotent stem cells: a stochastic advantage,” Development, vol. 141, no. 11, pp. 2173–2181, 2014. View at: Publisher Site | Google Scholar
  42. B. D. Macarthur and I. R. Lemischka, “Statistical mechanics of pluripotency,” Cell, vol. 154, no. 3, pp. 484–489, 2013. View at: Publisher Site | Google Scholar
  43. T. Enver, M. Pera, C. Peterson, and P. W. Andrews, “Stem cell states, fates, and the rules of attraction,” Cell Stem Cell, vol. 4, no. 5, pp. 387–397, 2009. View at: Publisher Site | Google Scholar
  44. K. Hayashi, S. M. C. D. S. Lopes, F. Tang, and M. A. Surani, “Dynamic equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and epigenetic states,” Cell Stem Cell, vol. 3, no. 4, pp. 391–401, 2008. View at: Publisher Site | Google Scholar
  45. S.-Y. Hatano, M. Tada, H. Kimura et al., “Pluripotential competence of cells associated with Nanog activity,” Mechanisms of Development, vol. 122, no. 1, pp. 67–79, 2005. View at: Publisher Site | Google Scholar
  46. I. Chambers, J. Silva, D. Colby et al., “Nanog safeguards pluripotency and mediates germline development,” Nature, vol. 450, no. 7173, pp. 1230–1234, 2007. View at: Publisher Site | Google Scholar
  47. A. M. Singh, T. Hamazaki, K. E. Hankowski, and N. Terada, “A heterogeneous expression pattern for Nanog in embryonic stem cells,” Stem Cells, vol. 25, no. 10, pp. 2534–2542, 2007. View at: Publisher Site | Google Scholar
  48. Y. Toyooka, D. Shimosato, K. Murakami, K. Takahashi, and H. Niwa, “Identification and characterization of subpopulations in undifferentiated ES cell culture,” Development, vol. 135, no. 5, pp. 909–918, 2008. View at: Publisher Site | Google Scholar
  49. D. W. Han, N. Tapia, J. Y. Joo et al., “Epiblast stem cell subpopulations represent mouse embryos of distinct pregastrulation stages,” Cell, vol. 143, no. 4, pp. 617–627, 2010. View at: Publisher Site | Google Scholar
  50. N. Festuccia, R. Osorno, F. Halbritter et al., “Esrrb is a direct Nanog target gene that can substitute for Nanog function in pluripotent cells,” Cell Stem Cell, vol. 11, no. 4, pp. 477–490, 2012. View at: Publisher Site | Google Scholar
  51. R. M. Kumar, P. Cahan, A. K. Shalek et al., “Deconstructing transcriptional heterogeneity in pluripotent stem cells,” Nature, vol. 516, no. 7529, pp. 56–61, 2014. View at: Publisher Site | Google Scholar
  52. H. Niwa, K. Ogawa, D. Shimosato, and K. Adachi, “A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells,” Nature, vol. 460, no. 7251, pp. 118–122, 2009. View at: Publisher Site | Google Scholar
  53. M. Zalzman, G. Falco, L. V. Sharova et al., “Zscan4 regulates telomere elongation and genomic stability in ES cells,” Nature, vol. 464, no. 7290, pp. 858–863, 2010. View at: Publisher Site | Google Scholar
  54. T. Kalmar, C. Lim, P. Hayward et al., “Regulated fluctuations in Nanog expression mediate cell fate decisions in embryonic stem cells,” PLoS Biology, vol. 7, no. 7, Article ID e1000149, 2009. View at: Publisher Site | Google Scholar
  55. B. D. Macarthur, A. Sevilla, M. Lenz et al., “Nanog-dependent feedback loops regulate murine embryonic stem cell heterogeneity,” Nature Cell Biology, vol. 14, no. 11, pp. 1139–1147, 2012. View at: Publisher Site | Google Scholar
  56. Y. Miyanari and M.-E. Torres-Padilla, “Control of ground-state pluripotency by allelic regulation of Nanog,” Nature, vol. 483, no. 7390, pp. 470–473, 2012. View at: Publisher Site | Google Scholar
  57. D. A. Faddah, H. Wang, A. W. Cheng, Y. Katz, Y. Buganim, and R. Jaenisch, “Single-cell analysis reveals that expression of nanog is biallelic and equally variable as that of other pluripotency factors in mouse ESCs,” Cell Stem Cell, vol. 13, no. 1, pp. 23–29, 2013. View at: Publisher Site | Google Scholar
  58. A. Filipczyk, K. Gkatzis, J. Fu et al., “Biallelic expression of nanog protein in mouse embryonic stem cells,” Cell Stem Cell, vol. 13, no. 1, pp. 12–13, 2013. View at: Publisher Site | Google Scholar
  59. P. Navarro, N. Festuccia, D. Colby et al., “OCT4/SOX2-independent Nanog autorepression modulates heterogeneous Nanog gene expression in mouse ES cells,” The EMBO Journal, vol. 31, no. 24, pp. 4547–4562, 2012. View at: Publisher Site | Google Scholar
  60. H. Ochiai, T. Sugawara, T. Sakuma, and T. Yamamoto, “Stochastic promoter activation affects Nanog expression variability in mouse embryonic stem cells,” Scientific Reports, vol. 4, article 7125, 2014. View at: Publisher Site | Google Scholar
  61. E. Abranches, A. M. Guedes, M. Moravec et al., “Stochastic NANOG fluctuations allow mouse embryonic stem cells to explore pluripotency,” Development, vol. 141, no. 14, pp. 2770–2779, 2014. View at: Publisher Site | Google Scholar
  62. S. van der Laan, E. Golfetto, J.-M. Vanacker, and D. Maiorano, “Cell cycle-dependent expression of Dub3, Nanog and the p160 family of nuclear receptor coactivators (NCoAs) in mouse embryonic stem cells,” PLoS ONE, vol. 9, no. 4, Article ID e93663, 2014. View at: Publisher Site | Google Scholar
  63. X. Zhang, I. Neganova, S. Przyborski et al., “A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A,” Journal of Cell Biology, vol. 184, no. 1, pp. 67–82, 2009. View at: Publisher Site | Google Scholar
  64. D. A. G. Card, P. B. Hebbar, L. Li et al., “Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cell,” Molecular and Cellular Biology, vol. 28, no. 20, pp. 6426–6438, 2008. View at: Publisher Site | Google Scholar
  65. K. B. Scotland, S. Chen, R. Sylvester, and L. J. Gudas, “Analysis of Rex1 (Zfp42) function in embryonic stem cell differentiation,” Developmental Dynamics, vol. 238, no. 8, pp. 1863–1877, 2009. View at: Publisher Site | Google Scholar
  66. H. S. Yoon and V. W. Yang, “Requirement of Krüppel-like factor 4 in preventing entry into mitosis following DNA damage,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 5035–5041, 2004. View at: Publisher Site | Google Scholar
  67. M. H. Stewart, M. Bossé, K. Chadwick, P. Menendez, S. C. Bendall, and M. Bhatia, “Clonal isolation of hESCs reveals heterogeneity within the pluripotent stem cell compartment,” Nature Methods, vol. 3, no. 10, pp. 807–815, 2006. View at: Publisher Site | Google Scholar
  68. K. K. Niakan, H. Ji, R. Maehr et al., “Sox17 promotes differentiation in mouse embryonic stem cells by directly regulating extraembryonic gene expression and indirectly antagonizing self-renewal,” Genes and Development, vol. 24, no. 3, pp. 312–326, 2010. View at: Publisher Site | Google Scholar
  69. M. A. Canham, A. A. Sharov, M. S. H. Ko, and J. M. Brickman, “Functional heterogeneity of embryonic stem cells revealed through translational amplification of an early endodermal transcript,” PLoS Biology, vol. 8, no. 5, 2010. View at: Publisher Site | Google Scholar
  70. T. Kobayashi, H. Mizuno, I. Imayoshi, C. Furusawa, K. Shirahige, and R. Kageyama, “The cyclic gene Hes1 contributes to diverse differentiation responses of embryonic stem cells,” Genes & Development, vol. 23, no. 16, pp. 1870–1875, 2009. View at: Publisher Site | Google Scholar
  71. S. Hough, M. Thornton, E. Mason, J. Mar, C. Wells, and M. Pera, “Single-cell gene expression profiles define self-renewing, pluripotent, and lineage primed states of human pluripotent stem cells,” Stem Cell Reports, vol. 2, no. 6, pp. 881–895, 2014. View at: Publisher Site | Google Scholar
  72. H. Marks, T. Kalkan, R. Menafra et al., “The transcriptional and epigenomic foundations of ground state pluripotency,” Cell, vol. 149, no. 3, pp. 590–604, 2012. View at: Publisher Site | Google Scholar
  73. F. Yi, L. Pereira, J. A. Hoffman et al., “Opposing effects of Tcf3 and Tcf1 control Wnt stimulation of embryonic stem cell self-renewal,” Nature Cell Biology, vol. 13, no. 7, pp. 762–770, 2011. View at: Publisher Site | Google Scholar
  74. J. Wray, T. Kalkan, S. Gomez-Lopez et al., “Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the pluripotency network and increases embryonic stem cell resistance to differentiation,” Nature Cell Biology, vol. 13, no. 7, pp. 838–845, 2011. View at: Publisher Site | Google Scholar
  75. N. Lyashenko, M. Winter, D. Migliorini, T. Biechele, R. T. Moon, and C. Hartmann, “Differential requirement for the dual functions of β-catenin in embryonic stem cell self-renewal and germ layer formation,” Nature Cell Biology, vol. 13, no. 7, pp. 753–761, 2011. View at: Publisher Site | Google Scholar
  76. D. T. Berge, D. Kurek, T. Blauwkamp et al., “Embryonic stem cells require Wnt proteins to prevent differentiation to epiblast stem cells,” Nature Cell Biology, vol. 13, no. 9, pp. 1070–1077, 2011. View at: Publisher Site | Google Scholar
  77. Y. Chen, K. Blair, and A. Smith, “Robust self-renewal of rat embryonic stem cells requires fine-tuning of glycogen synthase kinase-3 inhibition,” Stem Cell Reports, vol. 1, no. 3, pp. 209–217, 2013. View at: Publisher Site | Google Scholar
  78. A. M. Singh, M. Bechard, K. Smith, and S. Dalton, “Reconciling the different roles of Gsk3β in ‘naïve’ and ‘primed’ pluripotent stem cells,” Cell Cycle, vol. 11, no. 16, pp. 2991–2996, 2012. View at: Publisher Site | Google Scholar
  79. F. D. Price, H. Yin, A. Jones, W. van Ijcken, F. Grosveld, and M. A. Rudnicki, “Canonical Wnt signaling induces a primitive endoderm metastable state in mouse embryonic stem cells,” Stem Cells, vol. 31, no. 4, pp. 752–764, 2013. View at: Publisher Site | Google Scholar
  80. L. Marucci, E. Pedone, U. Di Vicino, B. Sanuy-Escribano, M. Isalan, and M. Cosma, “β-catenin fluctuates in mouse ESCs and is essential for Nanog-mediated reprogramming of somatic cells to pluripotency,” Cell Reports, vol. 8, no. 6, pp. 1686–1696, 2014. View at: Publisher Site | Google Scholar
  81. K. C. Davidson, A. M. Adams, J. M. Goodson et al., “Wnt/β-catenin signaling promotes differentiation, not self-renewal, of human embryonic stem cells and is repressed by Oct4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 12, pp. 4485–4490, 2012. View at: Publisher Site | Google Scholar
  82. T. A. Blauwkamp, S. Nigam, R. Ardehali, I. L. Weissman, and R. Nusse, “Endogenous Wnt signalling in human embryonic stem cells generates an equilibrium of distinct lineage-specified progenitors,” Nature Communications, vol. 3, article 1070, 2012. View at: Publisher Site | Google Scholar
  83. K. E. Galvin-Burgess, E. D. Travis, K. E. Pierson, and J. L. Vivian, “TGF-β-superfamily signaling regulates embryonic stem cell heterogeneity: self-renewal as a dynamic and regulated equilibrium,” Stem Cells, vol. 31, no. 1, pp. 48–58, 2013. View at: Publisher Site | Google Scholar
  84. E. Mason, J. Mar, A. Laslett et al., “Gene expression variability as a unifying element of the pluripotency network,” Stem Cell Reports, vol. 3, no. 2, pp. 365–377, 2014. View at: Publisher Site | Google Scholar
  85. A. B. Pardee, “A restriction point for control of normal animal cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 71, no. 4, pp. 1286–1290, 1974. View at: Publisher Site | Google Scholar
  86. D. S. Dimitrova and D. M. Gilbert, “The spatial position and replication timing of chromosomal domains are both established in early G1 phase,” Molecular Cell, vol. 4, no. 6, pp. 983–993, 1999. View at: Publisher Site | Google Scholar
  87. D. M. Gilbert, “Cell fate transitions and the replication timing decision point,” The Journal of Cell Biology, vol. 191, no. 5, pp. 899–903, 2010. View at: Publisher Site | Google Scholar
  88. D. Grün, L. Kester, and A. van Oudenaarden, “Validation of noise models for single-cell transcriptomics,” Nature Methods, vol. 11, no. 6, pp. 637–640, 2014. View at: Publisher Site | Google Scholar
  89. F. Buettner, K. N. Natarajan, F. P. Casale et al., “Computational analysis of cell-to-cell heterogeneity in single-cell RNA-sequencing data reveals hidden subpopulations of cells,” Nature Biotechnology, vol. 33, no. 2, pp. 155–160, 2015. View at: Publisher Site | Google Scholar
  90. S. A. Smallwood, H. J. Lee, C. Angermueller et al., “Single-cell genome-wide bisulfite sequencing for assessing epigenetic heterogeneity,” Nature Methods, vol. 11, no. 8, pp. 817–820, 2014. View at: Publisher Site | Google Scholar
  91. C. Lorthongpanich, L. F. Cheow, S. Balu et al., “Single-cell DNA-methylation analysis reveals epigenetic chimerism in preimplantation embryos,” Science, vol. 341, no. 6150, pp. 1110–1112, 2013. View at: Publisher Site | Google Scholar
  92. T. Nagano, Y. Lubling, T. J. Stevens et al., “Single-cell Hi-C reveals cell-to-cell variability in chromosome structure,” Nature, vol. 502, no. 7469, pp. 59–64, 2013. View at: Publisher Site | Google Scholar

Copyright © 2015 Amar M. Singh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.